Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male~* Age ≥ 18~* Diagnosis of having advanced melanoma , stage III-IV~* Scheduled for clinically indicated anti-PD-1 immunotherapy~* Informed Consent as documented by signature~* FDG PET/CT within 4 weeks before screening~* Biopsy available~* Minimum 3 lesions detected in FDG PET/CT~Exclusion Criteria:~* Age under 18~* Ocular melanoma~* Women who are pregnant or breast feeding,~* Intention to become pregnant during the course of the study,~* Previous enrolment into the current study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons,~* Previous immunotherapy,~* History of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment~* The subject has a known allergy to or has had an adverse reaction to dextran exposure~* Insufficient knowledge of project language, inability to give consent or to follow procedures~* The patient makes use of his/her right not to know and refuses to be informed about incidental findings

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Patients diagnosed with advanced melanoma (stage III-IV) will receive IV 250 µg Tilmanocept, labelled with 370 MBq of Tc-99m before the first cycle of clinically scheduled anti-PD-1 immunotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).